ZFIN ID: ZDB-FISH-180511-1
Fish name: cyp21a2uob2122/uob2122
Genotype: cyp21a2uob2122/uob2122
Targeting Reagent: none
HUMAN DISEASE MODELED by cyp21a2uob2122/uob2122
No data available
GENE EXPRESSION
Gene expression in cyp21a2uob2122/uob2122
RNA expression
Expressed Gene Structure Conditions Figures
cyp17a2 standard conditions Fig. 2 with image from Eachus et al., 2017
fkbp5 standard conditions Fig. 4 from Eachus et al., 2017
hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
pck1 standard conditions Fig. 4 from Eachus et al., 2017
hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
pomca standard conditions Fig. 4Fig. S3 with image from Eachus et al., 2017
hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in cyp21a2uob2122/uob2122
Phenotype Conditions Figures
adenohypophysis pomca expression increased distribution, abnormal standard conditions Fig. S3 with image from Eachus et al., 2017
cellular response to light stimulus disrupted, abnormal lighting conditions Fig. S2 with image from Eachus et al., 2017
cellular response to osmotic stress disrupted, abnormal hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
hypophysis increased size, abnormal standard conditions Fig. S3 with image from Eachus et al., 2017
interrenal gland hyperplastic, abnormal standard conditions Fig. 2 with image from Eachus et al., 2017
interrenal gland cyp17a2 expression increased distribution, abnormal standard conditions Fig. 2 with image from Eachus et al., 2017
interrenal gland increased size, abnormal standard conditions Fig. 2 with image from Eachus et al., 2017
melanocyte melanosome position, abnormal lighting conditions Fig. S2 with image from Eachus et al., 2017
melanosome localization disrupted, abnormal lighting conditions Fig. S2 with image from Eachus et al., 2017
neurohypophysis pomca expression increased distribution, abnormal standard conditions Fig. S3 with image from Eachus et al., 2017
steroid biosynthetic process process quality, abnormal standard conditions Fig. 3 from Eachus et al., 2017
steroid biosynthetic process process quality, abnormal hypertonic, chemical treatment: sodium chloride Fig. 3 from Eachus et al., 2017
whole organism pck1 expression decreased amount, abnormal hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
whole organism fkbp5 expression decreased amount, abnormal hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
whole organism fkbp5 expression decreased amount, abnormal standard conditions Fig. 4 from Eachus et al., 2017
whole organism pck1 expression decreased amount, abnormal standard conditions Fig. 4 from Eachus et al., 2017
whole organism pomca expression increased amount, abnormal standard conditions Fig. 4 from Eachus et al., 2017
whole organism pomca expression increased amount, abnormal hypertonic, chemical treatment: sodium chloride Fig. 4 from Eachus et al., 2017
whole organism 17alpha-hydroxyprogesterone present, abnormal standard conditions Fig. 3 from Eachus et al., 2017
whole organism 17alpha-hydroxyprogesterone present, abnormal hypertonic, chemical treatment: sodium chloride Fig. 3 from Eachus et al., 2017
whole organism 21-deoxycortisol increased amount, abnormal hypertonic, chemical treatment: sodium chloride Fig. 3 from Eachus et al., 2017
whole organism 21-deoxycortisol present, abnormal standard conditions Fig. 3 from Eachus et al., 2017
whole organism cortisol decreased amount, abnormal hypertonic, chemical treatment: sodium chloride Fig. 3 from Eachus et al., 2017
whole organism cortisol decreased amount, abnormal standard conditions Fig. 3 from Eachus et al., 2017

CITATIONS  (1)